Psyched Wellness (CSE: PSYC) this morning provided an update on its study to determine the therapeutic aspects of muscimol as both an antioxidant and an anti-inflammatory. Initial results have determined that no allergenic properties have been found within a series of tests.
More specifically, the study is focused on the firms proprietary AME-1 extract, which contains the active compound muscimol. The study is focused on determining the potential for antioxidant and anti-inflammatory properties of the formulation. An initial set of preclinical tests have been completed on the extract, which determined that there are no allergenic properties to be found based on an invitro cell-based mast cell model.
The findings are significant, in that it supports the thesis that AME-1 is not allergenic, which means that the extract will not show signs of hypersensitivity when the extract is used within supplements. Further studies are to be conducted on the formulation to further support these initial findings, while other studies on the extract and its potential properties are underway.
“The research from these studies supports what we already believe—that this special compound will have therapeutic benefits. It is our job to continue to work hard to uncover AME-1’s potential, and our research and development team will continue to examine all potential ways that that Amanita Muscaria can have positive impacts on health and wellness.”
Jeff Stevens, CEO of Psyched Wellness
Psyched Wellness last traded at $0.37 on the CSE.
FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
